These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39442347)

  • 1. PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients.
    Kleiburg F; de Geus-Oei LF; Luelmo SAC; Spijkerman R; Goeman JJ; Toonen FAJ; Smit F; van der Hulle T; Heijmen L
    Eur J Radiol; 2024 Dec; 181():111774. PubMed ID: 39442347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy.
    Jafari E; Manafi-Farid R; Ahmadzadehfar H; Salek F; Jokar N; Keshavarz A; Divband G; Dadgar H; Zohrabi F; Assadi M
    Nuklearmedizin; 2024 Dec; 63(6):347-358. PubMed ID: 39227023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [
    Muniz M; Sartor O; Orme JJ; Koch RM; Rosenow HR; Mahmoud AM; Andrews JR; Kase AM; Riaz IB; Belge Bilgin G; Thorpe MP; Kendi AT; Johnson GB; Ravi P; Kwon ED; Childs DS
    J Nucl Med; 2024 Dec; 65(12):1932-1938. PubMed ID: 39477495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Posttherapy 4- and 24-Hour [
    Swiha M; Pathmanandavel S; Papa N; Sabahi Z; Li S; Zheng A; Khan S; Ayers M; Sharma S; Crumbaker M; Nguyen A; Chan L; Ayati N; Emmett L
    J Nucl Med; 2024 Dec; 65(12):1939-1944. PubMed ID: 39477497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of rechallenge with [
    Santo G; Di Santo G; Sviridenko A; Bayerschmidt S; Wirth L; Scherbauer F; Lehmann P; von Guggenberg E; Decristoforo C; Heidegger-Pircher I; Bektic J; Virgolini I
    Eur J Nucl Med Mol Imaging; 2024 Dec; 52(1):354-365. PubMed ID: 39225826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [
    Pabst KM; Mei R; Lückerath K; Hadaschik BA; Kesch C; Rawitzer J; Kessler L; Bodensieck LS; Hamacher R; Pomykala KL; Fanti S; Herrmann K; Fendler WP
    Eur J Nucl Med Mol Imaging; 2024 Dec; 52(1):342-353. PubMed ID: 39207485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving
    Demirci RA; Gulati R; Hawley JE; Yezefski T; Haffner MC; Cheng HH; Montgomery RB; Schweizer MT; Yu EY; Nelson PS; Chen DL; Iravani A
    J Nucl Med; 2024 Dec; 65(12):1945-1951. PubMed ID: 39510589
    [No Abstract]   [Full Text] [Related]  

  • 9. Correlation of [
    Giunta EF; Caroli P; Scarpi E; Altavilla A; Rossetti V; Marini I; Celli M; Casadei C; Lolli C; Schepisi G; Bleve S; Brighi N; Cursano MC; Paganelli G; Matteucci F; De Giorgi U
    Eur J Nucl Med Mol Imaging; 2024 Dec; 52(1):326-334. PubMed ID: 39207484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical prostatectomy versus deferred treatment for localised prostate cancer.
    Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline Nodal Status on
    Hofman MS; Kasivisvanathan V; Link E; Buteau J; Roberts MJ; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Iravani A; Williams S; O'Brien J; Lawrentschuk N; Murphy DG
    Eur Urol Oncol; 2024 Nov; ():. PubMed ID: 39613566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the SORG Machine-learning Algorithm for Extremity Metastases Generalize to a Contemporary Cohort of Patients? Temporal Validation From 2016 to 2020.
    de Groot TM; Ramsey D; Groot OQ; Fourman M; Karhade AV; Twining PK; Berner EA; Fenn BP; Collins AK; Raskin K; Lozano S; Newman E; Ferrone M; Doornberg JN; Schwab JH
    Clin Orthop Relat Res; 2023 Dec; 481(12):2419-2430. PubMed ID: 37229565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage Hodgkin's lymphoma.
    Goldkuhle M; Kreuzberger N; von Tresckow B; Eichenauer DA; Specht L; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD007110. PubMed ID: 39620432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.
    Huang RR; Zuo C; Mona CE; Holzgreve A; Morrissey C; Nelson PS; Brady L; True L; Sisk A; Czernin J; Calais J; Ye H
    J Nucl Med; 2024 Dec; 65(12):1952-1958. PubMed ID: 39477498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilar monoclonal antibodies for cancer treatment in adults.
    Galvao TF; Livinalli A; Lopes LC; Zimmermann IR; Silva MT
    Cochrane Database Syst Rev; 2024 Nov; 11(11):CD013539. PubMed ID: 39607013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
    Bossi A; Foulon S; Maldonado X; Sargos P; MacDermott R; Kelly P; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Salem N; Calabro F; Berdah JF; Hasbini A; Silva M; Boustani J; Ribault H; Fizazi K;
    Lancet; 2024 Nov; 404(10467):2065-2076. PubMed ID: 39580202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Combination AKT and Androgen Receptor Signaling Inhibition in Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis.
    Nahar TAK; Bantounou MA; Savin I; Chohan N; Kumar NS; Ghose A; McEwan IJ
    Clin Genitourin Cancer; 2024 Dec; 22(6):102244. PubMed ID: 39549658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Ai J; Jian L; Wen X; Huo X; Yang X; Jiang J; Zhang T
    Clin Transl Oncol; 2024 Oct; 26(10):2559-2571. PubMed ID: 38750344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antioxidants for female subfertility.
    Showell MG; Mackenzie-Proctor R; Jordan V; Hart RJ
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD007807. PubMed ID: 32851663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.